Lyrica    (DrugBank: -)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
298遺伝性膵炎2

298. 遺伝性膵炎 [臨床試験数:93,薬物数:168(DrugBank:51),標的遺伝子数:48,標的パスウェイ数:134
Searched query = "Hereditary pancreatitis", "Chronic pancreatitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 93 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-010266-28-NL
(EUCTR)
21/07/200929/01/2009Een gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis - Effect van pregabaline therapie bij patiënten met chronische pancreatitisEen gerandomiseerde dubbelblinde, placebogecontroleerde, klinische parallelle groep studie van pregabaline in patiënten met chronische pancreatitis - Effect van pregabaline therapie bij patiënten met chronische pancreatitis chronische pancreatitis
MedDRA version: 9.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis
Trade Name: Lyrica® Afdeling heelkunde, Universitair Medisch Centrum Sint RadboudNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
30Netherlands
2EUCTR2008-002671-27-DK
(EUCTR)
14/07/200830/05/2008A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITISA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL AND EXPERIMENTAL PILOTSTUDY OF PREGABALIN IN PATIENTS WITH CHRONIC PANCREATITIS Chronic pancreatitis
MedDRA version: 9.1;Level: LLT;Classification code 10033649;Term: Pancreatitis chronic
Trade Name: Lyrica
INN or Proposed INN: pregabalin
INN or Proposed INN: Pregabalin
Department of Medical GastroenterologyNULLNot RecruitingFemale: yes
Male: yes
45Phase 3Denmark